Monthly Archives: April 2010

The Segregation of Social Media from Traditional Media – Why You Shouldn’t Do It

Posted on April 20, 2010 by Mark Senak

 When it comes to social media – journalists are getting confusing signs. In the last quarter of 2009, - the Bulldog Reporter/TEKgroup International 2009 Journalist Survey on Media Relations Practices  surveyed over 2300 journalists and does so on an annual basis to … Continue reading →

Posted in Uncategorized | Comments Off on The Segregation of Social Media from Traditional Media – Why You Shouldn’t Do It

DDMAC Erupts – A Troika of DDMAC Regulatory Action Letters

Posted on April 19, 2010 by Mark Senak

(NOTE:  After the initial publication of this posting, information was sent to me regarding FDA's Guidance on Risk Information – the posting was changed to note this important update and re-published.  The change is noted in italics in the third … Continue reading →

Posted in Warning Letters | 2 Comments

Weekly Roundup – 4/16/10

Posted on April 16, 2010 by Mark Senak

Springtime abounds.  I am still laid quite low by record levels of tree pollen, as I believe, are many others.  I am a first time sufferer and have new respect for those who have borne life-long allergies.  I see beautiful … Continue reading →

Posted in Uncategorized | Comments Off on Weekly Roundup – 4/16/10

How Social Media Could Improve FDA AdComm Meetings, Part 2

Posted on April 13, 2010 by Mark Senak

 What if the FDA held virtual meetings?  It could get more input more often from more people for less money.  What if they held virtual AdComm meetings?  Wouldn't that be great?  It isn't far fetched, it just requires vision.   … Continue reading →

Posted in Uncategorized | 1 Comment

How Social Media Could Improve FDA AdComm Meetings, Part 1

Posted on April 12, 2010 by Mark Senak

i-Pad, therefore i-Am.   A colleague asked me the other day – what is so special about the i-Pad that you don't already get on your phone or your laptop?   I responded by saying that right now, in computing, … Continue reading →

Posted in Advisory Committee Prepapartion, FDA Policy, New and Social Media | 1 Comment